$8.660
-0.856 (-9.89%)Zum Schluss
MSLE im Vergleich zur Peergroup
In the context of the broader market, MSLE competes directly with industry leaders such as ELDN and NMRA. With a market capitalization of $183.73M, it holds a significant position in the sector. When comparing efficiency, MSLE's gross margin of N/A stands against ELDN's N/A and NMRA's N/A. Such benchmarking helps identify whether Satellos Bioscience Inc. is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Satellos Bioscience Inc
Satellos has been experiencing significant net losses, with the latest reported net income of -11,718,000 USD for Q2 2026. The company has a current ratio of 11.22, indicating strong liquidity, but the overall financial health is challenged by ongoing losses.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.